Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade II Neuroendocrine Carcinoma”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Ended earlyNCT02315625
What this trial is testing

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT02489903
What this trial is testing

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Who this might be right for
Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors+1 more
EpicentRx, Inc. 139
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Testing effectiveness (Phase 2)Ended earlyNCT03042780
What this trial is testing

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more
H. Lee Moffitt Cancer Center and Research Institute 2
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Looking for participantsNCT06161532
What this trial is testing

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Who this might be right for
Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00663429
What this trial is testing

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine Carcinoma
Callisto Pharmaceuticals 10
Testing effectiveness (Phase 2)Study completedNCT03352934
What this trial is testing

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Who this might be right for
Cancer
Johannes Gutenberg University Mainz 60
Large-scale testing (Phase 3)Study completedNCT01298323
What this trial is testing

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Who this might be right for
Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer
Sanofi 205
Testing effectiveness (Phase 2)WithdrawnNCT03901378
What this trial is testing

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site
Ochsner Health System
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06228066
What this trial is testing

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Who this might be right for
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT00388063
What this trial is testing

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine Carcinoma
Callisto Pharmaceuticals 55
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Study completedNCT03728361
What this trial is testing

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Who this might be right for
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine Carcinoma+9 more
Dwight Owen 55
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)UnknownNCT04525638
What this trial is testing

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours (NET)Neuroendocrine Carcinomas (NEC)
Fundación de investigación HM 30
Testing effectiveness (Phase 2)Study completedNCT00427349
What this trial is testing

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Who this might be right for
Gastrointestinal Carcinoid TumorIslet Cell TumorNeoplastic Syndrome
Eastern Cooperative Oncology Group 46
Next Page
60